Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 99.0%

Apollomics, Inc. (NASDAQ:APLMW) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 700 shares, a decline of 99.0% from the December 31st total of 68,200 shares. Based on an average trading volume of 82,000 shares, the short-interest ratio is currently 0.0 days.

Apollomics Stock Up 0.9 %

NASDAQ:APLMW opened at $0.01 on Thursday. Apollomics has a 52 week low of $0.01 and a 52 week high of $0.04. The firm’s 50-day simple moving average is $0.01 and its 200 day simple moving average is $0.01.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.